LIDCO GROUP PLC

("LiDCO" or the "Company")

Grant of share option

LiDCO Group Plc (AIM:LID), the UK-based hemodynamic monitoring company, today announces that on 3 July 2012, in accordance with the rules of the Company's EMI Share Option Scheme, an option was granted to Mr Paul Clifford, the Company's Finance Director, to subscribe for new ordinary shares of 0.5 pence each ("Ordinary Shares") in the Company. The option is exercisable at 18.38 pence per Ordinary Share for a period of seven years from 3 July 2015. Details of Mr Clifford's interests are set out below:

Director             Number of      Total number      Number of      % of existing

                            options            of options            shares held      share capital

    granted            now held     

___________________________________________________________________

Paul Clifford        145,448           941,931               600,000             0.34%

- Ends -

For further information, please contact:

Media enquiries:

About LiDCO Group Plc

LiDCO is a supplier of minimally invasive hemodynamic monitoring equipment and disposables to hospitals. These products are used primarily for the management of adult hospital patients requiring critical care or at major cardiovascular risk. LiDCO's computer-based technology can significantly reduce the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London. LiDCO is based in the UK and its shares are traded on AIM. For more information please see www.lidco.com.

The Company's sales office is in Cambridge, its manufacturing facility / general administration base is in Hoxton, London, and its current products are:

* LiDCOplus is a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%)

* LiDCOrapid: our new cardiac output monitor designed specifically for use in the Operating Theatre for fluid and drug management. The monitor enables acute-care physicians to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being both during and after surgery.  These benefits are:

* LiDCO single-patient-use disposables used in conjunction with the LiDCOplus and LiDCOrapid.

* LiDCOview:an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.

*  LiDCO's Distribution Network:

The Company sells via its own direct sales force to hospitals in the UK, and in export markets predominantly through a worldwide network of specialty critical care and anesthesia distributors.